Giulia Fonti, PhD

Development and preclinical evaluation of next generation T cell gene-engineering strategies targeting solid tumors.

Responsible for leading a cross-functional team of scientist (6+) establishing two new research laboratories dedicated to the production of biologics in suspension-adapted mammalian cells and a new facility for the production of adeno-associated viruses (AAV) as gene therapy vectors.

CRISPR-Cas9 genome engineering using primary bronchial epithelial cells for the generation of 3D tissue reporter gene models.

Purification of human recombinant proteins in GMP downstream processing laboratory.

Design and development of an effective pipeline to discover and to screen new compounds against an attractive therapeutic target involved in the development of several hematological malignancies and unresponsive to canonical inhibitors used in clinics.